Pulmonary Arterial Hypertension - Pipeline Review, H2 2018

Publisher Name :
Date: 07-Aug-2018
No. of pages: 269
Inquire Before Buying

Pulmonary Arterial Hypertension - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2018, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 9, 11, 20, 35, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 4 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Pulmonary Arterial Hypertension - Pipeline Review, H2 2018

Table of Contents
Table of Contents 2
Introduction 5
Pulmonary Arterial Hypertension - Overview 6
Pulmonary Arterial Hypertension - Therapeutics Development 7
Pulmonary Arterial Hypertension - Therapeutics Assessment 20
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development 32
Pulmonary Arterial Hypertension - Drug Profiles 55
Pulmonary Arterial Hypertension - Dormant Projects 244
Pulmonary Arterial Hypertension - Discontinued Products 247
Pulmonary Arterial Hypertension - Product Development Milestones 248
Appendix 259

List of Tables
Number of Products under Development for Pulmonary Arterial Hypertension, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Acceleron Pharma Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Actelion Pharmaceuticals Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Aerogen Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H2 2018
Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Bayer AG, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca SA, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Biogen Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Bristol-Myers Squibb Co, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Camurus AB, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Capricor Therapeutics Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Celsion Corp, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Celtaxsys Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Chiesi Farmaceutici SpA, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Complexa Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Denovo Biopharma LLC, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Co, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by GlaxoSmithKline Plc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Insmed Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Insys Therapeutics Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Japan Tobacco Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Liquidia Technologies Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by MannKind Corp, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Nissan Chemical Industries Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Northern Therapeutics Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Pulmokine Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Relief Therapeutics Holding AG, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Roivant Sciences Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Serodus ASA, H2 2018
Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Suda Pharmaceuticals Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Toray Industries Inc, H2 2018
Pulmonary Arterial Hypertension - Pipeline by United Therapeutics Corp, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Vicore Pharma AB, H2 2018
Pulmonary Arterial Hypertension - Pipeline by Vivus Inc, H2 2018
Pulmonary Arterial Hypertension - Dormant Projects, H2 2018
Pulmonary Arterial Hypertension - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Pulmonary Arterial Hypertension, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018
  • Global and Chinese Myocardial Infarction Drugs Industry, 2018 Market Research Report
    Published: 10-Dec-2018        Price: US 3000 Onwards        Pages: 136
    The 'Global and Chinese Myocardial Infarction Drugs Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Myocardial Infarction Drugs industry with a focus on the Chinese market. The report provides key statistics on the market status of the Myocardial Infarction Drugs manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview......
  • Global and Chinese Rosuvastatin Industry, 2018 Market Research Report
    Published: 10-Dec-2018        Price: US 3000 Onwards        Pages: 150
    The 'Global and Chinese Rosuvastatin Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Rosuvastatin industry with a focus on the Chinese market. The report provides key statistics on the market status of the Rosuvastatin manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, ap......
  • Global and Chinese Rosuvastatin Calcium Industry, 2018 Market Research Report
    Published: 09-Dec-2018        Price: US 3000 Onwards        Pages: 139
    The 'Global and Chinese Rosuvastatin Calcium Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Rosuvastatin Calcium industry with a focus on the Chinese market. The report provides key statistics on the market status of the Rosuvastatin Calcium manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry incl......
  • Global and Chinese Atorvastatin Calcium Industry, 2018 Market Research Report
    Published: 09-Dec-2018        Price: US 3000 Onwards        Pages: 149
    The 'Global and Chinese Atorvastatin Calcium Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Atorvastatin Calcium industry with a focus on the Chinese market. The report provides key statistics on the market status of the Atorvastatin Calcium manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry incl......
  • Global Myocardial Ischemia Drugs Market Insights, Forecast to 2025
    Published: 04-Dec-2018        Price: US 3900 Onwards        Pages: 117
    In 2017, the global Myocardial Ischemia Drugs market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Myocardial Ischemia Drugs market based on company, product type, application and key regions. This report studies the global market size of Myocardial Ischemia Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle E......
  • Investigation Report on China’s Rosuvastatin Market, 2018-2022
    Published: 29-Nov-2018        Price: US 2200 Onwards        Pages: 30
    Rosuvastatin was first developed by Japanese company Shionogi & Co., Ltd. in the late 1980s. In Jun. 1998, Shionogi & Co., Ltd. transferred the right to develop, market and sell Rosuvastatin worldwide to AstraZeneca. The development code of Rosuvastatin by AstraZeneca is ZD-4522. Rosuvastatin was first approved in the Netherlands on Nov. 7, 2002, approved by the Health Council of Canada in Feb. 2003, and by the FDA on Aug. 12, 2003. The trade name of Astra......
  • Global Heart Failure Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 29-Nov-2018        Price: US 3480 Onwards        Pages: 135
    The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast pe......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Heart Failure Drugs Market 2018, Forecast to 2023
    Published: 29-Nov-2018        Price: US 4880 Onwards        Pages: 137
    The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast pe......
  • Global Simvastatin Market Data Survey Report 2025
    Published: 27-Nov-2018        Price: US 1500 Onwards        Pages: 69
    Summary The global Simvastatin market will reach Volume Million USD in 2018 with CAGR xx% 2019-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers (manufacturing sites, capacity and production, product specifications etc.) Major Application Major Type Key manufacturers are included based on manufacturing sites, capacity and prod......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs